Treatment Paradigm for Metastatic Upper GI Cancers

Opinion
Video

Dr Klempner and the Oncology Brothers discuss the treatment paradigm for patients with metastatic upper GI cancers.

Recent Videos
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Related Content
The safety profile of TFOX was consistent with data reported in previous studies, and no new safety signals were identified.

TFOX Regimen Enhances Efficacy vs FOLFOX in HER2-Negative Gastric Cancer

Roman Fabbricatore
May 11th 2025
Article

The safety profile of TFOX was consistent with data reported in previous studies, and no new safety signals were identified.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

"[G]iven the improvements in compliance and tolerability of the de-escalated regimen in older patients, with preserved early cancer outcomes, this reduced-dose regimen could be considered a new treatment option for [patients who are] frailer [and] not fit for standard-dose chemoradiotherapy," according to the study authors.

Chemoradiation Shows Responses Across Dose Levels in Anal Cancer

Russ Conroy
May 9th 2025
Article

Phase 2 data indicate that reduced-dose chemoradiotherapy may be tolerable among patients with early-stage anal cancer.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Phase 2 Actuate-1801 part 3B trial results evaluating elraglusib with GnP in metastatic PDAC will be presented at the 2025 ASCO Annual Meeting.

Elraglusib Combo Demonstrates OS Benefit in Metastatic Pancreatic Cancer

Roman Fabbricatore
May 8th 2025
Article

Phase 2 Actuate-1801 part 3B trial results evaluating elraglusib with GnP in metastatic PDAC will be presented at the 2025 ASCO Annual Meeting.

Pathological complete response was higher among patients with ERBB2–positive gastric cancer or GEJ adenocarcinoma treated with atezolizumab vs without.

Atezolizumab/Trastuzumab Plus Chemotherapy Shows Efficacy in Gastric Cancer

Roman Fabbricatore
May 7th 2025
Article

Pathological complete response was higher among patients with ERBB2–positive gastric cancer or GEJ adenocarcinoma treated with atezolizumab vs without.